Grufity logo
Grufity logo
CLRB

CLRB - Cellectar Biosciences Inc Stock Price, Fair Value and News

$2.40+0.06 (+2.56%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

Price Targets

CLRB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CLRB Price Action

Last 7 days

-6.4%

Last 30 days

-23.9%

Last 90 days

-28.8%

Trailing 12 Months

-80.9%

CLRB RSI Chart

CLRB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CLRB Valuation

Market Cap

10.2M

Price/Earnings (Trailing)

-0.49

Price/Sales (Trailing)

306.96

EV/EBITDA

-0.08

Price/Free Cashflow

-0.55

CLRB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

CLRB Fundamentals

CLRB Revenue

Revenue (TTM)

44.5K

CLRB Earnings

Earnings (TTM)

-20.8M

Earnings Growth (Yr)

14.39%

Earnings Growth (Qtr)

-6.77%

CLRB Profitability

EBT Margin

-48991.74%

Return on Equity

-624.9%

Return on Assets

-187.42%

Free Cashflow Yield

-182.64%

CLRB Investor Care

Shares Dilution (1Y)

176.05%

Diluted EPS (TTM)

-6.07

CLRB Alerts

  • 2 major insider buys recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2011161.1K122.2K83.4K44.5K
2010---200.0K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Cellectar Biosciences Inc

CLRB
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
 CEO
 WEBSITEcellectar.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES15

Cellectar Biosciences Inc Frequently Asked Questions

CLRB is the stock ticker symbol of Cellectar Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of Cellectar Biosciences Inc is 9.92 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, CLRB's PE ratio (Price to Earnings) is -0.48 and Price to Sales (PS) ratio is 306.96. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CLRB PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Cellectar Biosciences Inc has provided -0.57 (multiply by 100 for percentage) rate of return.